Protocol Ledger

NCT07700979 · Phase III · RECRUITING

Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic G

Interventional Phase III clinical trial protocol NCT07700979 sponsored by Akeso in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-09-24 Enrollment: 900 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07700979
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)900 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07700979
Protocol FieldVerified Registry Value
NCT IdentifierNCT07700979
Consolidated Lead SponsorAkeso
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment900 participants (ESTIMATED)
Registered Start Date2026-09-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI